Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development

Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, announced it has been awarded a $19 million, five-year grant to fund the development of SBS-518 from IND submission through Phase 1 clinical development. Sparian Biosciences has exclusive rights to technology from Dr. Christopher McCurdy, a UF Innovate researcher, and professor and the Frank A. Duckworth Eminent Scholar Chair at the University of Florida College of Pharmacy.

SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD). StUD is a subset of substance use disorders that includes cocaine and methamphetamine use disorders. The grant was awarded by NIH/NIDA under the Help End Addiction Long-Term (HEAL) initiative.

SBS-518 is being developed in collaboration with the National Institute of Drug Abuse (NIDA), University of Florida College of Pharmacy, and the Harvard Medical School-McLean Hospital.

Read more about Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development.